"Meditab Holdings Ltd, Mauritius, a wholly owned subsidiary of the company, has entered into a definitive agreement to sell its entire 48.22 per cent equity interest in Jiangsu Cdymax Pharmaceuticals Co Ltd, China to an affiliate of one of the other shareholders of Jiangsu, for a total consideration of $18.5 million," Cipla said in a filing to the Bombay Stock Exchange.
The closing of the transaction is subject to receipt of applicable regulatory approvals in China, it added.
Representative image. Photograph: Reuters
Ranbaxy, Sun Pharma gain as CCI clears deal
Telangana allocates 11,000 acre land for mega pharma city
Ranbaxy brand may fade away as Sun takes charge
Investors' wealth crosses Rs 100 trillion
Sensex rises after a steep fall; Tata Steel, Hindalco up